- Home
- OVID
as 03-27-2025 11:48am EST
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 47.1M | IPO Year: | 2017 |
| Target Price: | $3.03 | AVG Volume (30 days): | 289.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.37 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.35 - $3.45 | Next Earning Date: | 03-11-2025 |
| Revenue: | $566,000 | Revenue Growth: | 44.39% |
| Revenue Growth (this year): | -33.77% | Revenue Growth (next year): | -25.85% |
Stock Insider Trading Activity of Ovid Therapeutics Inc. (OVID)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rona Jeffrey A | OVID | CBFO | Feb 26 '25 | Sell | $0.56 | 3,902 | $2,185.12 | 67,973 | |
| ALEXANDER MARGARET A. | OVID | President and COO | Feb 26 '25 | Sell | $0.56 | 5,279 | $2,956.24 | 73,406 | |
| ALEXANDER MARGARET A. | OVID | President and COO | Jan 27 '25 | Buy | $0.73 | 6,810 | $4,971.30 | 34,935 |
Latest Ovid Therapeutics Inc. News
OVID Breaking Stock News: Dive into OVID Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
MT Newswires
17 days ago
Wedbush Adjusts Price Target on Ovid Therapeutics to $3 From $4, Keeps Outperform Rating
Zacks
18 days ago
Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
GlobeNewswire
18 days ago
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Simply Wall St.
18 days ago
We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate
GlobeNewswire
a month ago
Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors
GlobeNewswire
a month ago
Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
2 months ago
Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Compare OVID vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OVID Ovid Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.